UCB share price breaks through €219 and surges nearly 12% following raised targets
The Belgian pharmaceutical company is enjoying one of the strongest trading sessions in its recent history. The stock is reacting to the upward revision of its annual outlook and erasing some of the decline suffered in recent months.
2026 target raise driven by Bimzelx success in the United States
The stock gains 11.92% to €238.40, compared to €213 at the previous close, and shows an 18.02% increase over the week. UCB raised its 2026 targets in a statement released today. The group now anticipates growth in its adjusted EBITDA approximately twice as rapid as that of its revenues, with revenue growth expected in the lower end of the twenty percent range.
The statement attributes this raise to Bimzelx and Cimzia, whose volumes and net prices are more favorable in the United States. It also cites a contracting anti-TNF market, on which Cimzia is nonetheless making progress in volume. The move comes as the CAC 40 falls 1.51% in trading, which heightens the contrast with the Paris market.
The €219 threshold is crossed, the 200-day moving average remains within reach
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock has exceeded its 30-day high at €219, a level that becomes a support. The price is now 15% above the 20-day moving average (€207.26) and close to 13% above the 50-day moving average (€211.14), while the RSI at 71 signals an overbought configuration following such rapid gains. The 200-day moving average at €241.62 remains slightly above the price, with a 1.33% gap.
Regarding analyst views, Oddo BHF lowered its target on October 20 from €293 to €260, while maintaining its outperform opinion. This target is 9% above the current price. The next resistance level is at €275.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: FY2026
Guidance from the release
higher 2026 expectations, with revenue growth anticipated in the low twenties
Risks mentioned
Marché des anti-TNF en contraction : CIMZIA y progresse encore en volume, mais sur un marché qui recule.
Opportunities identified
BIMZELX plus fort aux États-Unis : demande des patients soutenue et prix nets plus favorables.
CIMZIA : contribution solide, croissance des volumes et prix plus favorables.
Effet de levier opérationnel : la croissance plus forte du chiffre d'affaires élargit nettement la marge.
Outlook / guidance
Management commentary: Continued strong performance supports higher 2026 expectations, with revenue growth anticipated in the low twenties at constant exchange rates, up from low- to mid-teens Higher revenue growth is driving significant operating leverage, with adjusted EBITDA growth expected in the low- to mid-forties at constant exchange rates, up from mid-teens to low-twenties
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
